HomeAboutRankingsData Sources
© 2026 GeneE
🧬
GeneE
10 sources retrieved · Most recent: April 2026 · Index updated 14 days ago
ⓘGeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
P2RY2
purinergic receptor P2Y2
Chromosome 11 · 11q13.4
NCBI Gene: 5029Ensembl: ENSG00000175591.13HGNC: HGNC:8541UniProt: P41231
142PubMed Papers
20Diseases
3Drugs
0Pathogenic Variants
FUNCTIONAL ROLE
Receptor
CLINICAL
FDA Approved Target
DATA QUALITY
✓ Experimental GO Evidence✓ Swiss-Prot Reviewed
protein bindingG protein-coupled purinergic nucleotide receptor signaling pathwayplasma membraneG protein-coupled UTP receptor activitynontoxic goiterdry eye syndromeeye diseasecystic fibrosis
✦AI Summary

P2RY2 is a G protein-coupled purinergic receptor that binds ATP and UTP with equal affinity, activating phospholipase C-mediated calcium signaling pathways 1. The receptor is widely distributed throughout human tissues, including the gastrointestinal tract where it plays important roles in epithelial barrier function and ion transport, particularly chloride flux regulation in airway epithelia 12. P2RY2 demonstrates significant clinical relevance in cancer progression, where it promotes tumor growth through activation of AKT/GSK-3β/VEGF and PI3K/AKT-mTOR signaling pathways 34. In gastric cancer, P2RY2 activation enhances cell proliferation, migration, and epithelial-mesenchymal transition markers 3. Similarly, in pancreatic ductal adenocarcinoma, P2RY2 promotes glycolytic metabolism and tumor growth through crosstalk with PDGFR signaling, leading to upregulation of c-Myc and HIF1α 4. The receptor also contributes to esophageal squamous cell carcinoma progression via circRNA-mediated mRNA stabilization 5. Interestingly, naturally occurring antibodies against P2RY2 are decreased in Alzheimer's disease patients, suggesting potential involvement in neurodegeneration 6. These findings position P2RY2 as both a potential therapeutic target for cancer treatment and a biomarker for various diseases.

Sources cited
1
P2RY2 is a G protein-coupled receptor with equal affinity for ATP and UTP, coupling to phospholipase C signaling and having widespread tissue distribution including roles in chloride transport
PMID: 11111826
2
P2RY2 is expressed in gastrointestinal epithelium and responds to purinergic signaling in human intestinal organoids
PMID: 37987757
3
P2RY2 promotes gastric cancer cell proliferation and migration through AKT/GSK-3β/VEGF signaling pathway activation
PMID: 36469496
4
P2RY2 promotes pancreatic cancer growth by enhancing glycolysis through PI3K/AKT-mTOR signaling and upregulation of c-Myc and HIF1α
PMID: 30420446
5
P2RY2 contributes to esophageal squamous cell carcinoma progression through circRNA-mediated mRNA stabilization
PMID: 40858175
6
Naturally occurring antibodies against P2RY2 are decreased in Alzheimer's disease patients
PMID: 35342089
Disease Associationsⓘ20
nontoxic goiterOpen Targets
0.44Moderate
dry eye syndromeOpen Targets
0.40Moderate
eye diseaseOpen Targets
0.37Weak
cystic fibrosisOpen Targets
0.37Weak
cholelithiasisOpen Targets
0.35Weak
multinodular goiterOpen Targets
0.34Weak
preeclampsiaOpen Targets
0.23Weak
endocrine neoplasmOpen Targets
0.12Weak
breast cancerOpen Targets
0.11Weak
retinal detachmentOpen Targets
0.08Suggestive
hepatocellular carcinomaOpen Targets
0.08Suggestive
neoplasmOpen Targets
0.08Suggestive
HIV-1 infectionOpen Targets
0.08Suggestive
non-small cell lung carcinomaOpen Targets
0.08Suggestive
depressive disorderOpen Targets
0.08Suggestive
liver dysplastic noduleOpen Targets
0.08Suggestive
ganglioneuromaOpen Targets
0.08Suggestive
acute respiratory distress syndromeOpen Targets
0.07Suggestive
macular retinal edemaOpen Targets
0.07Suggestive
Rhinitis, Allergic, PerennialOpen Targets
0.07Suggestive
Pathogenic Variants
No pathogenic variants reported on ClinVar for this gene.
View on ClinVar ↗
Drug Targets3
DENUFOSOL TETRASODIUMPhase III
Purinergic receptor P2Y2 agonist
cystic fibrosis
DIQUAFOSOLApproved
Pyrimidinergic receptor P2Y6 agonist
eye disease
DIQUAFOSOL TETRASODIUMPhase III
Pyrimidinergic receptor P2Y6 agonist
dry eye syndrome
Related Genes
PLCB1Protein interaction100%PLCB3Protein interaction100%GNAQProtein interaction99%P2RX2Protein interaction98%P2RX6Protein interaction97%ENTPD8Protein interaction91%
Tissue Expression6 tissues
Bone Marrow
100%
Heart
62%
Lung
39%
Liver
30%
Brain
7%
Ovary
3%
Gene Interaction Network
Click a node to explore
P2RY2PLCB1PLCB3GNAQP2RX2P2RX6ENTPD8
PROTEIN STRUCTURE
Preparing viewer…
PDB9K20 · 2.65 Å · EM
View on RCSB ↗
Constraintⓘ
LOEUFⓘ
1.92LoF Tolerant
pLIⓘ
0.14Tolerant
Observed/Expected LoF1.47 [0.31–1.92]
RankingsWhere P2RY2 stands among ~20K protein-coding genes
  • #3,228of 20,598
    Most Researched142 · top quartile
  • #906of 1,025
    FDA-Approved Drug Targets1
  • #17,376of 17,882
    Most Constrained (LOEUF)1.92
Genes detectedP2RY2
Sources retrieved10 papers
Response time—
📄 Sources
10▼
1
Circulating Naturally Occurring Antibodies to P2RY2 Are Decreased in Alzheimer's Disease.
PMID: 35342089
J Alzheimers Dis · 2022
1.00
2
Upregulation of has_circ_0008389 promotes esophageal squamous cell carcinoma progression via miR-761 sponging and P2RY2 mRNA stabilization.
PMID: 40858175
Int J Biol Macromol · 2025
0.90
3
AKT/GSK-3beta/VEGF signaling is involved in P2RY2 activation-induced the proliferation and metastasis of gastric cancer.
PMID: 36469496
Carcinogenesis · 2023
0.80
4
Molecular pharmacology of P2Y-receptors.
PMID: 11111826
Naunyn Schmiedebergs Arch Pharmacol · 2000
0.70
5
Identification of exosomal microRNAs and related hub genes associated with imatinib resistance in chronic myeloid leukemia.
PMID: 38916832
Naunyn Schmiedebergs Arch Pharmacol · 2024
0.60